INVAGESIC FORTE
Clinical safety rating
cautionComprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
| Metabolism | Codeine is metabolized via CYP2D6 to morphine, and via CYP3A4 to norcodeine. Ibuprofen is metabolized primarily via CYP2C9. |
| Excretion | Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5% |
| Half-life | Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in CrCl <30 mL/min) |
| Protein binding | 99% (primarily albumin; binding reduced in hypoalbuminemia, uremia, and neonates) |
| Volume of Distribution | 0.1-0.2 L/kg (clinical meaning: low Vd indicates limited extravascular distribution, consistent with high protein binding and acidic drug nature) |
| Bioavailability | Oral: 80-100% (food delays absorption but does not reduce extent) |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 10-20 minutes; Intravenous: 1-2 minutes |
| Duration of Action | Oral: 4-6 hours; Intramuscular/Intravenous: 2-4 hours (clinical notes: analgesic effect wanes before anti-inflammatory effect due to central vs peripheral COX inhibition) |
| Molecular Weight | 288.8 |
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate impairment (eGFR 30-59 mL/min/1.73 m²): use lowest effective dose, maximum 4 tablets per day; avoid in dialysis. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). For class B (moderate): reduce dose by 50% and monitor; do not exceed 4 tablets per day. Class A (mild): no adjustment but caution. |
| Pediatric use | Not recommended for pediatric patients under 18 years of age due to risk of serious adverse effects. |
| Geriatric use | Start at lower end of dosing range (e.g., 1 tablet every 6 hours); maximum 4 tablets per day. Avoid in patients with creatinine clearance < 30 mL/min. Monitor for renal function, hepatic function, and gastrointestinal bleeding. |
| 1st trimester | Avoid use during first trimester due to potential teratogenicity; limited human data, but NSAIDs are associated with increased risk of miscarriage and malformations. |
| 2nd trimester | Use with caution; may cause oligohydramnios and premature ductus arteriosus constriction; minimal exposure if necessary. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for INVAGESIC FORTE (INVAGESIC FORTE).
| Placental transfer | Crosses placenta; detected in fetal cord blood with transfer rate approximately 1-2% of maternal concentration. |
| Breastfeeding | Excreted into breast milk in low amounts. Consider risk of infant gastrointestinal and renal effects; avoid use in breastfeeding mothers, especially with prolonged therapy. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category D for NSAID component (diclofenac): Avoid in third trimester due to risk of premature ductus arteriosus closure and oligohydramnios. First and second trimester use associated with increased risk of miscarriage and cardiac malformations. Paracetamol component is generally considered low risk but chronic high doses may increase risk of fetal hepatotoxicity. |
| Fetal Monitoring | Monitor fetal ultrasound for ductus arteriosus patency and amniotic fluid index if NSAID used beyond 20 weeks gestation. Assess maternal renal function and hepatic function if prolonged therapy. Observe newborn for potential withdrawal or adverse effects if maternal use near term. |
| Fertility Effects | NSAIDs may impair female fertility by inhibiting prostaglandin synthesis involved in ovulation; effect is reversible upon discontinuation. No data on male fertility for this combination. |
■ FDA Black Box Warning
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); neonatal opioid withdrawal syndrome; risk from concomitant use with benzodiazepines or other CNS depressants; cytochrome P450 2D6 ultra-rapid metabolizers (risk of life-threatening respiratory depression from codeine).
| Serious Effects |
Hypersensitivity to INVAGESIC FORTE or any componentActive peptic ulcer disease or gastrointestinal bleedingSevere heart failure (NYHA III-IV)Severe hepatic impairment (Child-Pugh C)Severe renal impairment (eGFR <30 mL/min)History of asthma, urticaria, or other allergic-type reactions after taking aspirin or NSAIDsCoronary artery bypass graft (CABG) surgery perioperative painThird trimester of pregnancy
| Precautions | Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; ultra-rapid metabolism of codeine (CYP2D6); gastrointestinal bleeding (NSAIDs); cardiovascular thrombotic events; renal toxicity; hepatic impairment; elderly patients; pregnancy. |
| Food/Dietary | Avoid grapefruit juice as it may increase tramadol levels. High-fat meals may delay absorption but not overall effect. No specific dietary restrictions beyond avoiding alcohol. |
| Clinical Pearls | Invagesic Forte (paracetamol 500 mg + tramadol 37.5 mg) is a fixed-dose combination analgesic. Tramadol is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy. Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. Maximum daily tramadol dose is 300 mg (8 tablets). Seizure risk increases in patients taking SSRIs, tricyclics, or with epilepsy. |
| Patient Advice | Take exactly as prescribed; do not exceed 8 tablets daily. · May cause dizziness or drowsiness; avoid driving or operating machinery. · Avoid alcohol while taking this medication. · Do not take with other medications containing acetaminophen (paracetamol) to avoid liver damage. · Report severe constipation, nausea, or difficulty breathing to your doctor. · Do not stop abruptly; withdrawal symptoms may occur. |
Loading safety data…